Navigation Links
Yale receives $8.4 million to study DNA repair in cancer cells
Date:10/25/2007

New Haven, Conn.Yale School of Medicine researchers have received $8.4 million to study how cancer cells mend their own chromosomes and DNA after damage caused by radiation and chemotherapy.

The study funded by the National Institutes of Health (NIH) is the next step in developing targeted cancer therapies, said the lead researcher, Peter Glazer, M.D., chair of therapeutic radiology and leader of the radiobiology research program at Yale Cancer Center.

We have put together a program to target protein and DNA repair enzymes that fix the DNA, Glazer said. We feel this could create an Achilles heel for cancer cells that would make them more vulnerable to traditional cancer therapies.

Cancer therapies such as radiation and chemotherapy work by damaging the cancer cells DNA, which carries the information, or blueprint, for cell replication.

Glazer said the four NIH funded Yale studies combine basic and translational research and may lead to new therapies for use with conventional radiation and chemotherapy.

It is our hope to be able to offer novel therapies derived from this research to our patients at the Yale Cancer Center, he said. The overall program represents a significant commitment of the Yale School of Medicine and the participating investigators to studies that have direct relevance to cancer biology and therapy.

In one research project, Alan Sartorelli, professor of pharmacology, will develop new cancer prodrugs that become activated in the low-oxygen conditions in which tumor cells can thrive. Once activated, the drug sets in motion the destruction of a resistance protein that repairs certain DNA lesions.

Glazer will lead a study of the cancer DNA repair genes, RAD51 and BRCA1, in cancer cells. His goal is to devise strategies to render cancer cells vulnerable to therapies that target interconnected repair pathways. RAD51 creates a protein that performs DNA repair and BRCA1 is a tumor suppressor associated with breast cancer.

Joann Sweasy, professor of therapeutic radiology, will study how DNA repair occurs in the normal human population and in tumors. She will examine how deficiencies in DNA repair can be used to guide the design of new cancer therapies.

Patrick Sung, professor of therapeutic radiology and of molecular biophysics and biochemistry, will focus on the repair genes BRCA2, FANCD2, and RAD51, and how their repair pathways are regulated at the level of protein-protein interactions.


'/>"/>

Contact: Jacqueline Weaver
jacqueline.weaver@yale.edu
203-432-8555
Yale University
Source:Eurekalert

Related biology news :

1. DuPonts first biologically derived polymer receives global recognition
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Research on antibiotics receives historical recognition
4. Anthrax test, developed by army and CDC, receives FDA approval
5. Research team receives $7.5 million to study cassava
6. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
7. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
8. Six million Africans face famine because of locusts, drought
9. Retrovirus struck ancestors of chimpanzees and gorillas millions of years ago, but did not affect ancestral humans
10. Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils
11. $5.1 billion would save 6 million children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... VANCOUVER, Canada and BADEN-BADEN, Germany ... Solutions, a leading global financial services provider, today announced an ... in passive behavioural biometrics, to join forces. The partnership will ... fraud mitigation strategies in compliance with local data protection regulation. ... In ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of ... growth is accounted to two main factors. The first is the amazing customer ... vendors supplying FireflySci products all around the world. , 2016 was a tremendous sales ...
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA ... FPGA into a compact business-card sized form factor suitable for prototyping, testing, and ...
Breaking Biology Technology: